New drug duo tested for Tough-to-Treat uterine cancer
NCT ID NCT05870761
Summary
This study is testing whether two drugs, niraparib and dostarlimab, work better together to treat a specific type of uterine cancer that has returned or persisted after previous treatment. The trial aims to see if this combination can shrink tumors and control the disease. It is for adults with recurrent or persistent uterine serous carcinoma who have already received standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.